Adam Duckett, DO
Family Medicine · Auburn, NYNPI 1497900633
Payments from drug & device makers
Across 244 payments — averaging $34.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- USWM, LLC$4K
- GSK$738
- Gilead$619
- Novo Nordisk$307
- Lilly USA, LLC$274
- AbbVie$248
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,27050%
- Gifts$4,18650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| USWM, LLC | 3 | $4,199 |
| GSK | 53 | $738 |
| Gilead | 34 | $619 |
| Novo Nordisk | 18 | $307 |
| Lilly USA, LLC | 16 | $274 |
| AbbVie | 14 | $248 |
| Pfizer | 13 | $228 |
| Johnson & Johnson | 12 | $214 |
| AstraZeneca | 13 | $200 |
| Alkermes, Inc. | 6 | $169 |
| Merck | 9 | $152 |
| Amgen | 7 | $143 |
| Indivior Inc. | 5 | $93 |
| Noah Medical Corporation | 1 | $89 |
| Boehringer Ingelheim | 5 | $76 |
| Braeburn Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Bayer | 2 | $40 |
| Mylan Specialty L.p. | 1 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Grifols USA, LLC | 2 | $37 |
| Insulet Corporation | 1 | $33 |
| Cequr Corporation | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| IBSA Pharma Inc. | 2 | $27 |
| Abbott | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Exact Sciences | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| MDD US Operations, LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| Biogen | 1 | $18 |
| Optinose US, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUCEMYRA$4,186
How this compares
$8,455 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 146 | $156,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $93,186 |
| EliquisApixaban | 83 | $59,612 |
| OzempicSemaglutide | 48 | $42,717 |
| MounjaroTirzepatide | 32 | $33,310 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $24,895 |
| XareltoRivaroxaban | 26 | $24,466 |
| JanuviaSitagliptin Phosphate | 15 | $17,520 |
| Repatha SureclickEvolocumab | 20 | $13,858 |
| EntrestoSacubitril/Valsartan | 15 | $10,121 |
| VascepaIcosapent Ethyl | 21 | $8,545 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,396 |
| Atorvastatin Calcium | 781 | $7,110 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $6,106 |
| MyrbetriqMirabegron | 11 | $5,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $274 | $189,951178 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $738 | $120,876183 claims |
| PfizerEliquis | $228 | $59,61283 claims |
| Novo NordiskOzempic | $307 | $42,71748 claims |
| Johnson & JohnsonXarelto | $214 | $24,46626 claims |
| MerckJanuvia | $152 | $17,52015 claims |
| Boehringer IngelheimSpiriva Respimat | $76 | $7,39614 claims |
| AstraZenecaSymbicort | $200 | $6,10620 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $5,08211 claims |
| AbbVieSynthroid | $248 | $93719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Auburn
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.